OnKure reports Q2 net loss $15.4M; OKI-219 trial data expected Q4 2025

OnKure Therapeutics, Inc.

Cash $83.4M as of June 30, 2025; runway expected into Q4 2026.
Q2 net loss $15.4M ($1.14/sh) vs $14.1M ($44.82/sh) YoY; R&D spend rose to $12.6M.
Completed enrollment in monotherapy and fulvestrant combo arms; data from both due Q4 2025.
New triplet arm initiated: OKI-219 + fulvestrant + ribociclib in HR+ metastatic breast cancer.
New triplet arm: OKI-219 + trastuzumab + tucatinib in HER2+ breast cancer; pan-mutant candidate nomination by year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.